Crescent BDC (CCAP) PT Lowered to $13 at Wells Fargo
Tweet
Share
E-mailGet Alerts CCAP Hot Sheet
Price: $10.68 -1.2%
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
5 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Wells Fargo analyst Finian O'Shea lowered the price target on Crescent BDC (NASDAQ: CCAP) to $13.00 (from $14.00) while maintaining a Equal Weight rating.
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Okta, Inc (OKTA) PT Raised to $170 at Cantor Fitzgerald Ahead of Q2 Results
- Nordson (NDSN) PT Raised to $370 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
